Multidisciplinary management of TNBC: Integrating immunotherapies for early and metastatic disease скачать в хорошем качестве

Multidisciplinary management of TNBC: Integrating immunotherapies for early and metastatic disease

💡 Confidently integrate immunotherapy into early-stage and metastatic TNBC Immunotherapy is a key component in the management of triple-negative breast cancer (TNBC), but knowing how to maximize its benefit in real-world practice is key. In this expert-led activity, Prof. Sherko Kümmel, Prof. Rebecca Dent and Prof. Peter Schmid share practical guidance on applying immunotherapy to treat early-stage and metastatic TNBC. Tailored for the breast cancer care team, the content translates the latest data and guideline recommendations into actionable strategies. 🎯 Gain insights into: ✅ Where immunotherapy fits in TNBC treatment pathways ✅ How to apply biomarker testing to personalize care ✅ Approaches to mitigate and manage immune-related side effects ✅ Strategies for patient-centred, multidisciplinary care 💬 Prof. Peter Schmid: “I think particularly for immunotherapy, multidisciplinary working is critical. No one can look after patients on their own and give them an optimal service. Oncologists are at the core of the multidisciplinary team.” 👉 Watch the expert insights now: https://touchoncologyime.org/manageme... This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. #TNBC #BreastCancer #OncologyEducation #Immunotherapy #IO #MedicalEducation #PatientCare #CancerTreatment